| VIS ID | Virus | Ensembl ID | Gene Type | Target Gene | Oncogene | Tumor Suppressor Gene | NCBI ID | Uniprot ID |
|---|---|---|---|---|---|---|---|---|
| TVIS10017570 | HBV | ENSG00000135914.6 | protein_coding | HTR2B | No | No | 3357 | P41595 |
| TVIS30010694 | HIV | ENSG00000135914.6 | protein_coding | HTR2B | No | No | 3357 | P41595 |
| TVIS30052490 | HIV | ENSG00000135914.6 | protein_coding | HTR2B | No | No | 3357 | P41595 |
| TVIS30052491 | HIV | ENSG00000135914.6 | protein_coding | HTR2B | No | No | 3357 | P41595 |
| TVIS30052492 | HIV | ENSG00000135914.6 | protein_coding | HTR2B | No | No | 3357 | P41595 |
| TVIS30052493 | HIV | ENSG00000135914.6 | protein_coding | HTR2B | No | No | 3357 | P41595 |
| TVIS30052494 | HIV | ENSG00000135914.6 | protein_coding | HTR2B | No | No | 3357 | P41595 |
Target Gene Table
▼
TCGA Plot Options
▼
Drug Information
▼
| Gene | HTR2B |
|---|---|
| DrugBank ID | DB00574 |
| Drug Name | Fenfluramine |
| Target ID | BE0000393 |
| UniProt ID | P41595 |
| Regulation Type | agonist |
| PubMed IDs | 10617681; 11104741; 12761331; 14659797; 16960982; 17202450; 28073790; 32169824; 10498829; 26822114; 28428755 |
| Citations | Fitzgerald LW, Burn TC, Brown BS, Patterson JP, Corjay MH, Valentine PA, Sun JH, Link JR, Abbaszade I, Hollis JM, Largent BL, Hartig PR, Hollis GF, Meunier PC, Robichaud AJ, Robertson DW: Possible role of valvular serotonin 5-HT(2B) receptors in the cardiopathy associated with fenfluramine. Mol Pharmacol. 2000 Jan;57(1):75-81.@@Rothman RB, Baumann MH, Savage JE, Rauser L, McBride A, Hufeisen SJ, Roth BL: Evidence for possible involvement of 5-HT(2B) receptors in the cardiac valvulopathy associated with fenfluramine and other serotonergic medications. Circulation. 2000 Dec 5;102(23):2836-41.@@Setola V, Hufeisen SJ, Grande-Allen KJ, Vesely I, Glennon RA, Blough B, Rothman RB, Roth BL: 3,4-methylenedioxymethamphetamine (MDMA, "Ecstasy") induces fenfluramine-like proliferative actions on human cardiac valvular interstitial cells in vitro. Mol Pharmacol. 2003 Jun;63(6):1223-9.@@Blanpain C, Le Poul E, Parma J, Knoop C, Detheux M, Parmentier M, Vassart G, Abramowicz MJ: Serotonin 5-HT(2B) receptor loss of function mutation in a patient with fenfluramine-associated primary pulmonary hypertension. Cardiovasc Res. 2003 Dec 1;60(3):518-28.@@Kaumann AJ, Levy FO: 5-hydroxytryptamine receptors in the human cardiovascular system. Pharmacol Ther. 2006 Sep;111(3):674-706.@@Roth BL: Drugs and valvular heart disease. N Engl J Med. 2007 Jan 4;356(1):6-9.@@Griffin A, Hamling KR, Knupp K, Hong S, Lee LP, Baraban SC: Clemizole and modulators of serotonin signalling suppress seizures in Dravet syndrome. Brain. 2017 Mar 1;140(3):669-683. doi: 10.1093/brain/aww342.@@Martin P, de Witte PAM, Maurice T, Gammaitoni A, Farfel G, Galer B: Fenfluramine acts as a positive modulator of sigma-1 receptors. Epilepsy Behav. 2020 Apr;105:106989. doi: 10.1016/j.yebeh.2020.106989. Epub 2020 Mar 10.@@Porter RH, Benwell KR, Lamb H, Malcolm CS, Allen NH, Revell DF, Adams DR, Sheardown MJ: Functional characterization of agonists at recombinant human 5-HT2A, 5-HT2B and 5-HT2C receptors in CHO-K1 cells. Br J Pharmacol. 1999 Sep;128(1):13-20.@@Sourbron J, Schneider H, Kecskes A, Liu Y, Buening EM, Lagae L, Smolders I, de Witte P: Serotonergic Modulation as Effective Treatment for Dravet Syndrome in a Zebrafish Mutant Model. ACS Chem Neurosci. 2016 May 18;7(5):588-98. doi: 10.1021/acschemneuro.5b00342. Epub 2016 Feb 17.@@Sourbron J, Smolders I, de Witte P, Lagae L: Pharmacological Analysis of the Anti-epileptic Mechanisms of Fenfluramine in scn1a Mutant Zebrafish. Front Pharmacol. 2017 Apr 6;8:191. doi: 10.3389/fphar.2017.00191. eCollection 2017. |
| Groups | Approved; Illicit; Investigational; Withdrawn |
| Direct Classification | Amphetamines and derivatives |
| SMILES | CCNC(C)CC1=CC=CC(=C1)C(F)(F)F |
| Pathways | |
| PharmGKB | PA449592 |
| ChEMBL | CHEMBL87493 |
